Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

by Gallant, Joel, Brunetta, Jason, Crofoot, Gordon, Benson, Paul, Mills, Anthony, Brinson, Cynthia, Oka, Shinichi, Cheng, Andrew, Garner, Will, Fordyce, Marshall, Das, Moupali, McCallister, Scott
Published 2016

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis

by Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max
Published 2014

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis

by Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max
Published 2014

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

by Raffi, François, Rachlis, Anita, Brinson, Cynthia, Arasteh, Keikawus, Górgolas, Miguel, Brennan, Clare, Pappa, Keith, Almond, Steve, Granier, Catherine, Nichols, W. Garrett, Cuffe, Robert Liam, Jr, Joseph Eron, Walmsley, Sharon
Published 2015